SciNeuro Pharmaceuticals https://validator.w3.org/feed/docs/rss2.html Science Once a GSK hopeful for heart disease, an inhibitor class makes a comeback in Alzheimer’s deal Footer Careers Deciphering the Enigma of Brain Disease SciNeuro completes dosing in its Phase 1 clinical trial of SNP318, an oral therapeutic for Alzheimer’s disease and other neurodegenerative diseases SciNeuro looks to give GSK Alzheimer’s program new life SciNeuro Pharmaceuticals to Accelerate Novel LRRK2 Therapeutic (SNP614) Development with an Award from The Michael J. Fox Foundation Pipeline_11_19 About Us SciNeuro Pharmaceuticals to Present Preclinical Efficacy and Safety Data on SNP614, a Novel Antisense Oligonucleotide Directed to LRRK2, at the 2024 International Congress of Parkinson’s Disease and Movement Disorders SciNeuro Main Header Contact Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology A TREM2 antibody energizes microglia SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer Our Team_draft Our Team SciNeuro Announces Exclusive Licensing Agreement with Eli Lilly & Company SciNeuro Pharmaceuticals Launches to Bring Innovative Treatments for CNS Diseases SciNeuro Participated in Alzheimer’s and Parkinson’s Disease Conference 2024, and Presented a Poster on Its Leading ASO Program SNP614 SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases SciNeuro Pharmaceuticals Announces the Appointment of Guojun Bu, Ph.D., as Chief Scientific Officer, and Provides Update on Pipeline of Novel CNS Therapeutics SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases SciNeuro to Join Endpoints Roundtable at BIO 2023 Protected: Pipeline Deciphering the enigma of brain disease SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer’s Disease Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases Pushing the boundaries of brain organoids to study Alzheimer’s disease News Deciphering the Enigma of Brain Disease __NEW Pipeline SciNeuro Pharmaceuticals and Alamar Biosciences Collaborate to Discover  Novel Therapeutic Antibodies for CNS Diseases Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease Protected: Careers ARCH, Lilly Asia Ventures return to back US-China startup SciNeuro Pipeline Careers